Organization
Abide Therapeutics, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Abide Therapeutics, Inc.
... Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in ...
... Abide Therapeutics, a developer of innovative pharmaceuticals, announced today the appointment of Sapna ...
... (Central Nervous System) pipeline landscape. Main companies ofTourette Syndrome pipeline H2are Abide Therapeutics Inc, Catalyst Pharmaceuticals Inc, Neurocrine Biosciences Inc, Psyadon Pharmaceuticals Inc, Reviva Pharmaceuticals ...
... Abide Therapeutics, a developer of innovative pharmaceuticals, announced today that new preclinical and ...
... Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in ...
... Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in ...
... than a decade of drug development success at Merck and now at Abide Therapeutics, where he has rapidly advanced the company's first drug into clinical ...
... �Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in ...
... Abide, a nonprofit group aimed at improving the inner city, has a new ...
... trade risk mitigation and information services,announces today that it hasacquired Abide Financial (Abide), a market-leading global regulatory reporting specialist. Abide will become a subsidiary of ...
... Abide Therapeutics announced today that Celgene has exercised its option to obtain ex-US ...
... Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and ...
... Board of Directors," said Alan Ezekowitz, MBChB, D.Phil., President and CEO of Abide Therapeutics. "We are confident that Rich will contribute to shaping our corporate ...
... for each program," said Alan Ezekowitz, MBChB, D.Phil., President and CEO of Abide Therapeutics. "With our first clinical study launched, the time is ideal to ...
... drug discovery and development expertise that will be a valuable asset to Abide Therapeutics as we continue to build out our therapeutic pipeline and advance ...
... Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and ...
... with the University of Oxford SAN DIEGO, Nov. 4, 2014 /PRNewswire/ -- Abide Therapeutics announced today that the Company has entered into a collaborative agreement ...
... scientific advisory board," said Alan Ezekowitz, MBChB, D.Phil., president and CEO of Abide Therapeutics. "As we advance our programs into the clinic, Nancy's in-depth knowledge ...
... Immune Disorders. SAN DIEGO and PRINCETON, N.J., Feb. 28, 2014 /PRNewswire/ -- Abide Therapeutics today announced it has entered into a strategic collaboration with Celgene ...
... Abide Therapeutics Appoints Dr. Gary O'Neill as Vice President of Biology Abide Therapeuticsannounces ...
... s disease is the goa l of new research announced today by Abide Therapeutics , in collaboration with researchers at the University of California, San ...
... Diego Awarded Grant from Cure Alzheimer's Fund to Validate Therapeutic Target . Abide Therapeutics and UC San Diego Awarded Grant from Cure Alzheimer's Fund to ...
... Tim Edwards (Chairman), Mark Payton (CEO), Alan Ezekowitz, CEO and Chairman of Abide Therapeutics and former SVP Respiratory and Immunology franchise at Merck Research Laboratories ...
... to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases . Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤